Efficacy Of Velpatasvir and Sofosbuvir Combination Therapy in Chronic HCV Patients

Hafiz Mughees  Ather; Affan  Shahid; Muhammad  Usama; Muhammad  Amir; Arfan  Mahmood; Umair  Waheed

doi:10.29054/apmc/2023.1283

Hafiz Mughees Ather Professor, Department of Gastroenterology, Faisalabad Medical University, Faisalabad Pakistan
Affan Shahid Consultant Gastroenterologist, Govt. General Hospital, GGH Faisalabad Pakistan
Muhammad Usama Senior Registrar, Sahiwal Medical College, Sahiwal Pakistan
Muhammad Amir Assistant Professor, Department of Medicine, Faisalabad Medical University, Faisalabad Pakistan
Arfan Mahmood Assistant Professor, Department of Gastroenterology, Faisalabad Medical University, Faisalabad Pakistan
Umair Waheed Senior Registrar, Department of Gastroenterology, Govt. General Hospital, Faisalabad Pakistan

DOI: https://doi.org/10.29054/apmc/2023.1283

Keywords: Hepatitis C, Sofosbuvir, Velpatasvir, Ribavirin, Naïve, HCV treatment in Faisalabad, Cirrhosis, Sustained virological response

Abstract

Background: Chronic Hepatitis C is a prevalent infection in Pakistan. It can lead to complications like cirrhosis of liver, liver failure, hepatocellular carcinoma and death. Oral antiviral therapy has revolutionized the treatment of Hepatitis C. It can achieve eradication of HCV in the form of sustained virological response in HCV patients. Objective: We conducted a study to analyze the efficacy of Sofosbuvir, Velpatasvir combination therapy with Ribavirin except when there was a contraindication. Study Design: Prospective single Centre cohort study. Settings: Ather gastro liver Centre, Faisalabad Pakistan. Duration: The study duration was one year from January 2019 to December 2019. Methods: Study including all chronic Hepatitis C patients who underwent treatment for Chronic hepatitis C virus (HCV) with Sofosbuvir (SOF) and Velpatasvir (VELPA) combination therapy with Ribavirin (Rib). All patients were more than 18 years old. Results: 64% patients were male and 36% were females. 8.5 % patients were cirrhotic and all patients received Ribavirin. SVR was achieved in 115 / 117 (98.29%) patients. Conclusion: Sofosbuvir, Velpatasvir combination therapy with Ribavirin is an effective antiviral therapy for the treatment of chronic hepatitis C.